

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 1093)

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND COMPLIANCE WITH RULE 13.92 OF THE LISTING RULES

Appointment of Independent Non-Executive Director

The Board of Directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”) is pleased to announce that Ms. Li Quan (“**Ms. Li**”) has been appointed as an independent non-executive director of the Company with effect from 8 November 2022.

The biographical details of Ms. Li are set out below:

Ms. Li Quan, aged 42, has over ten years of experience in investment management. She is currently the Managing Director of CDH Investments Management (Hong Kong) Limited, responsible for investment in the healthcare sector in the private equity department. Ms. Li holds a Bachelor of Cell Biology & Genetics and Economics double degree from Peking University, and a Master of Science degree from National University of Singapore School of Computing. She is also a non-executive director of SciClone Pharmaceuticals (Holdings) Limited (stock code: 6600), which is listed on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

Ms. Li has entered into a letter of appointment with the Company pursuant to which she has been appointed as an independent non-executive director without a specific term but subject to retirement and re-election at the general meeting in accordance with the Articles of Association of the Company. Ms. Li will be entitled to receive a director’s fee of HK\$157,500 per annum which was determined by the Board on the recommendation of the Remuneration Committee with reference to her experience, duties with the Company and prevailing market practices.

Ms. Li has not held any other positions with any members of the Group and does not have any relationships with any directors, senior management, substantial or controlling shareholders of the Company. Save as disclosed above, Ms. Li has not held any directorships in any listed public companies in the last three years. As at the date of this announcement, Ms. Li does not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Future Ordinance.

Save as disclosed above, there is no other information that is required to be disclosed pursuant to rule 13.51(2) of the Rules Governing the Listing of Securities of The Stock Exchange (the “**Listing Rules**”) nor any other matter which needs to be brought to the attention of the shareholders of the Company in connection with the appointment of Ms. Li.

The Board would like to take this opportunity to extend its warm welcome to Ms. Li on joining the Board.

Compliance with Rule 13.92 of the Listing Rules

Following the appointment of Ms. Li, the Board has achieved gender diversity and thus fulfils the requirement under Rule 13.92 of the Listing Rules.

By order of the board
CSPC Pharmaceutical Group Limited
CAI Dongchen
Chairman

Hong Kong, 8 November 2022

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.